Lung Neoplasms clinical trials in Florida

T cell activator STAR0602 for advanced solid tumors

This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.

Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors

This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.

A study of LY4175408 for advanced cancer

This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.

Testing a live tumor test for immune therapy response

This trial uses a special test on live tumor samples to see if it can predict how well immune checkpoint inhibitors (a type of immunotherapy) will work for different cancers. It may help doctors choose the best treatment for you.

Study of SGN-CEACAM5C for advanced solid tumors

This trial tests a new drug called SGN-CEACAM5C in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein on cancer cells to try to stop them from growing.

Study of MK-1084 plus other treatments for lung cancer

This trial tests a new drug (MK-1084) combined with other treatments for people with a specific type of advanced lung cancer (non-small cell, non-squamous) that has a KRAS G12C mutation. It is for those whose cancer has worsened after prior immunotherapy and chemotherapy.

Surgery vs focused radiation for early lung cancer

This trial compares two ways to treat early-stage lung cancer: surgery or a precise type of radiation called stereotactic radiotherapy. It aims to find out which approach works best for people whose cancer is small and has not spread.

Study medicine for BRAF-mutated advanced solid tumors

This Phase 1 trial studies how PF-07799544 works and what dose is safest in people with advanced cancer that has a specific genetic change called BRAF V600. You may receive it alone or with another treatment, depending on the tumor group, to see if it can treat the cancer.

Oloromosib with Immunotherapy as First Treatment for KRAS G12C Lung Cancer

This trial tests a new targeted pill (olomorasib) combined with immunotherapy (pembrolizumab) and possibly chemotherapy for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and has not been treated before.

Home cancer treatment program for Florida panhandle residents

This study tests whether people with certain cancers can safely receive their regular intravenous treatments at home instead of coming to the clinic. It aims to make treatment more convenient and improve satisfaction, especially for those living in the Florida Panhandle.

Memory-sparing radiation for brain metastases in small cell lung cancer

This study tests whether focusing high-dose radiation only on brain tumor spots, while avoiding the hippocampus (a brain area important for memory), helps protect memory and thinking compared with standard whole-brain radiation. It’s for people with small cell lung cancer that has spread to the brain.

CAR T cell therapy for mesothelin-positive solid tumors

This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.

Dose test of a DLL3 cancer drug for neuroendocrine tumors

This Phase 2 study tests how different doses of BI 764532 affect people with small cell lung cancer or certain other neuroendocrine cancers. It may help shrink tumors and improve symptoms after standard treatments have stopped working.

New KRAS-Targeting Drug for Advanced Solid Tumors

This early-stage trial tests BLU-924, a new drug designed to target cancer cells with specific KRAS mutations (a common genetic change in pancreatic, lung, and colon cancers). The study aims to find the right dose and see how well it works in patients whose cancers have progressed despite standard treatments.

Surgery choice for lung spread of osteosarcoma

This Phase 3 trial compares two ways to remove lung metastases (open surgery vs keyhole surgery) in people with osteosarcoma. It aims to see which approach works better and is safer for patients with a limited number of lung spots that can be removed.

Tumor-pulse device for spinal cancer fluid spread

This trial tests whether Tumor Treating Fields (a non-surgical device that delivers treatment signals to cancer cells through the scalp/skin) can help people whose breast or lung cancer has spread into the fluid around the spine and brain. It focuses on people who have cancer cells found in spinal fluid and can safely use the device most of the day.

Study of NKT3964 for advanced solid tumors

This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.

Proton vs standard radiation for cancer spread to brain/spine lining

This trial compares a newer type of radiation (proton therapy) to standard radiation for people whose breast or lung cancer has spread to the lining of the brain and spinal cord. It aims to see if proton therapy can better control the disease while causing fewer side effects.

Test apheresis for CAR T manufacturing in HLA-A2 solid tumors

This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Study drug for TP53 Y220C-mutated advanced cancers

This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.

Standard vs longer radiation for brain metastases

This trial compares the usual short course of radiation therapy (one session) to a longer course (up to 5 sessions) for people with cancer that has spread to the brain. The goal is to see if the longer course works better and causes fewer side effects.

Study of CID-078 for advanced solid tumors

This trial tests an experimental drug called CID-078 for people with advanced solid tumors that have stopped responding to other treatments. It aims to find the right dose and see if the drug can shrink tumors.

Nivolumab at home vs. clinic for cancer treatment

This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.